Skip to main content
Funded Studies

Lamp-2a as a Therapeutic Target in Parkinson's Disease

Multiple pieces of evidence converge on the notion that accumulation of the protein alpha-synuclein is important for Parkinson’s disease (PD) pathogenesis. One of the ways through which such accumulation could occur is through impairment of the mechanisms that normally degrade alpha-synuclein. We and others have shown that in cultured neuronal cells a major mechanism for alpha-synuclein degradation is that of chaperone-mediated autophagy (CMA), which occurs in lysosomes. Whether this occurs in the setting of a pre-clinical model, and whether induction of this degradation system in vivo can be used to get rid of excess alpha-synuclein, and thus confer therapeutic benefit in PD, is unknown.

Project Description: 
We will use a system of viral delivery, in which the gene of interest is expressed via an Adeno-Assocaited Virus (AAV), which infects the nigral dopaminergic neurons affected in PD with high efficiency. We will inject such viruses in the substantia nigra of a pre-clinical model using a stereotaxic approach for correct targeting, and thus express the protein products of 3 genes: EGFP, which is used as a control, Lamp-2a, whose expression has been shown to induce CMA, and alpha-synuclein. We will examine whether combined expression of Lamp2a together with alpha-synuclein diminishes the accumulation and aggregation of alpha-synuclein, as well as its toxic effects on nigral dopaminergic neurons.

Relevance to Diagnosis/Treatment of Parkinson’s Disease, Combined with Outcome:
This project will test the hypothesis that induction of CMA and subsequent enhanced clearance of alpha-synuclein may have beneficial effects in a relevant PD animal model. Should we be successful, this may pave the way for the use of such approaches, of enhancing CMA function, in order to diminish alpha-synuclein accumulation in PD. Such approaches could either be of the type of gene therapy employed here, or of the type of specific drugs that enhance CMA function. First, however, a proof of principle study, like the one proposed here, is needed in order to test that this strategy can be safe and effective in a pre-clinical model.

Final Outcome

We have found that overexpression of Lamp-2a, a protein that drives degradation of substrates through the lysosomes in a process known as chaperone-mediated autophagy (CMA), ameliorates the toxicity induced by overexpression of alpha-synuclein in a pre-clinical model substantia nigra. Importantly, using this approach, both nigral cell bodies and nigrostriatal terminals, as well as levels of dopamine, were preserved. Furthermore, total levels of alpha-synuclein, as well as specific aberrant species, were reduced when Lamp-2a was co-expressed. This implies that Lamp-2a overexpression enhanced the clearance of alpha-synuclein. Overall, these results support the idea that enhancement of CMA through Lamp-2a overexpression or other means, possibly pharmacological, may represent a therapeutic avenue to treat Parkinson’s disease and related synucleinopathies, in which excess and aberrant alpha-synuclein contributes to neurodegeneration. 


  • Leonidas Stefanis, MD, PhD

    Athens Greece

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.